drugset / Trial / NCT06291337

Ibuprofen Inhibits Human Sweet Taste

NCT06291337

Non-randomizedCrossoverOpen-labelBasic science

Summary

The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose absorption and metabolism. Recently, ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expressed in cells. In the present study, the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal, physiological conditions. Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli (sucrose, fructose, sucralose) after a prerinse of ibuprofen, naproxen or water. Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner. In association studies, ibuprofen use has been linked to preserved metabolic function, as its use is correlated with lower rates of Alzheimer's disease, diabetes and colon cancer. Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases.

Timeline

Start
2020-06-01
Primary completion
2023-09-01
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 0.12 unknown Other
Subject Ibuprofen Small molecule 0.18 unknown Other
Subject Ibuprofen Small molecule 0.24 unknown Other
Subject Ibuprofen Small molecule 0.57 unknown Other
Subject Ibuprofen Small molecule 5.7 unknown Other
Subject Naproxen Small molecule Other

Indications

No indication recorded.